Differential effects of selenium on benign and malignant prostate epithelial cells: Stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations

Nutrition and Cancer

Volumn 61, Issue 2, 2009, Pages 251-264

  Kandaş, Nur Özten ^a   Randolph, Carla ^b   Bosland, Maarten C ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; SELENITE; SELENIUM; SODIUM SELENITE;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MENTAL CONCENTRATION; NITROBLUE TETRAZOLIUM TEST; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY;

ANDROGENS; APOPTOSIS; CASPASE 3; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EPITHELIAL CELLS; HUMANS; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER; SELENIUM; SODIUM SELENITE; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 61649123090     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802398430     Document Type: Article

References (53)

1. Platz EA and Giovannucci E: The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92, 237-253, 2004. [Epub 2005 January 5].
2. Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 27, 39-66, 2000.
3. Klein EA: Chemoprevention of prostate cancer. Ann Rev Med 57, 49-63, 2006.
4. Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, et al.: Chemoprevention strategies for prostate cancer. Eur J Cancer Prev 11(2 Suppl), S18-S27, 2002.
5. Sinha R and El-Bayoumy K: Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 4, 13-28, 2004.
6. Clark LC, Combs GF Jr, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963, 1996. [Erratum in JAMA 277, 1520, 1997].
7. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al.: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11, 630-639, 2002.
8. Duffield-Lillico AJ, Slate EH, Reid ME, et al.: Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95, 1477-1481, 2003.
9. El-Bayoumy K, Upadhyaya P, Date V, Sohn OS, Fiala ES, et al.: Metabolism of [14C] benzyl selenocyanate in the F344 rat. Chem Res Toxicol 4, 560-565, 1991.
10. El-Bayoumy K, Das A, Narayanan B, Fiala ES, Desai D, et al.: Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer. Carcinogenesis 27, 1369-1376, 2006. [Epub 2006 January 6].
11. Brinkman M, Reulen RC, Kellen E, Buntinx F, and Zeegers MP: Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 42, 2463-2471, 2006. [Epub 2006 September 1].
12. Li H, Stampfer MJ, Giovannucci EL, et al.: A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96, 696-703, 2004.
13. Peters U, Foster CB, Chatterjee N, et al.: Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 85, 209-217, 2007.
14. Jiang C, Hu H, Malewicz B, Wang Z, and Lu J: Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 3, 877-884, 2004.
15. Ip C, Thompson HJ, Zhu Z, and Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60, 2882-2886, 2000.
16. Diwadkar-Navsariwala V and Diamond AM: The link between selenium and chemoprevention: a case for selenoproteins. J Nutr 134, 2899-2902, 2004.
17. Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr 128, 1845-1854, 1998.
18. Combs GF Jr: Considering the mechanisms of cancer prevention by selenium. Adv Exp Med Biol 492, 107-117, 2001.
19. El-Bayoumy K: Overview: the late Larry C. Clark showed the bright side of the moon element (selenium) in a clinical cancer prevention trial. Nutr Cancer 40, 4-5, 2001.
20. Fleming J, Ghose A, and Harrison PR: Molecular mechanisms of cancer prevention by selenium compounds. Nutr Cancer 40, 42-49, 2001.
21. Ganther HE: Selenium metabolism and mechanisms of cancer prevention. Adv Exp Med Biol 492, 119-130, 2001.
22. Kim YS and Milner J: Molecular targets for selenium in cancer prevention. Nutr Cancer 40, 50-54, 2001.
23. Lu J and Jiang C: Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer 40, 64-73, 2001.
24. Youn BW, Fiala ES, and Sohn OS: Mechanisms of organoselenium compounds in chemoprevention: effects on transcription factor-DNA binding. Nutr Cancer 40, 28-33, 2001.
25. Patrick L: Selenium biochemistry and cancer: a review of the literature. Altern Med Rev 9, 239-258, 2004.
26. Rayman MP: Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64, 527-542, 2005.
27. Arner ES and Holmgren A: The thioredoxin system in cancer. Semin Cancer Biol 16, 420-426, 2006. [Epub 2006 October 28].
28. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, et al.: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31, 14-24, 1995.
29. Holmgren A and Bjornstedt M: Thioredoxin and thioredoxin reductase. Methods Enzymol 252, 199-208, 1995.
30. Sells SF, Wood DP Jr., Joshi-Barve SS, et al.: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5, 457-466, 1994.
31. Rebsch CM, Penna FJ III, and Copeland PR: Selenoprotein expression is regulated at multiple levels in prostate cells. Cell Res 16, 940-948, 2006. [Erratum in Cell Res 17, 272, 2007].
32. Ghosh J: Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315, 624-635, 2004.
33. Novoselov SV, Calvisi DF, Labunskyy VM, et al.: Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 24, 8003-8011, 2005.
34. Nano JL, Czerucka D, Menguy F, and Rampal P: Effect of selenium on the growth of three human colon cancer cell lines. Biol Trace Elem Res 20, 31-43, 1989.
35. Zhu S, Gray TE, and Nettesheim P: The effect of sodium selenite on cell proliferation and transformation of primary rat tracheal epithelial cells. Carcinogenesis 13, 1725-1729, 1992.
36. Lee YC, Tang YC, Chen YH, Wong CM, and Tsou AP: Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1. J Biol Chem 278, 39615-39624, 2003.
37. Zhong W and Oberley TD: Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61, 7071-7078, 2001.
38. Menter DG, Sabichi AL, and Lippman SM: Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9, 1171-1182, 2000.
39. Zhou N, Xiao H, Li TK, Nur-E-Kamal A, and Liu LF: DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 278, 29532-29537, 2003. [Epub 2003 May 24].
40. Pagmantidis V, Méplan C, van Schothorst EM, Keijer J, and Hesketh JE: Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr 87, 181-189, 2008.
41. Bjorkhem-Bergman L, Jonsson K, Eriksson LC, et al.: Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity: effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol 63, 1875-1884, 2002. [Erratum in Biochem Pharmacol 64, 159, 2002].
42. Vogt TM, Ziegler RG, Patterson BH, and Graubard BI: Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 166, 280-288, 2007. [Epub 2007 June 8].
43. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, et al.: Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 11, 1285-1291, 2002.
44. Hill KE, Chittum HS, Lyons PR, Boeglin ME, and Burk RF: Effect of selenium on selenoprotein P expression in cultured liver cells. Biochim Biophys Acta 1313, 29-34, 1996.
45. Neve J: Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. J Trace Elem Med Biol 9, 65-73, 1995.
46. Gianduzzo TR, Holmes EG, Tinggi U, Shahin M, Mactaggart P, et al.: Prostatic and peripheral blood selenium levels after oral supplementation. J Urol 170, 870-873, 2003.
47. Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, et al.: Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev 28, 8-16, 2004.
48. Zachara BA, Szewczyk-Golec K, Tyloch J, et al.: Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia. Neoplasma 52, 248-254, 2005.
49. Pilat MJ, Kamradt JM, and Pienta KJ: Hormone resistance in prostate cancer. Cancer Metastasis Rev 17, 373-381, 1998-1999.
50. Gallegos A, Berggren M, Gasdaska JR, and Powis G: Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res 57, 4965-4970, 1997.
51. Nilsonne G, Sun X, Nystrom C, et al.: Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 41, 874-885, 2006. [Epub 2006 May 10].
52. Zhang J, Svehlikova V, Bao Y, Howie AF, Beckett GJ, et al.: Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation. Carcinogenesis 24, 497-503, 2003.
53. Lindner DJ, Hofmann ER, Karra S, and Kalvakolanu DV: The interferon-beta and tamoxifen combination induces apoptosis using thioredoxin reductase. Biochim Biophys Acta 1496, 196-206, 2000.